Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2630)	1/22/2001 10:45:12 AM
From: Biomaven	Read Replies (1) of 52153

Here's the FDA review of approvals in 2000: fda.gov Overall, not a very exciting year for drug approvals. In Fiscal Years 1999 and 2000, FDA reviewed 100% of new molecular entities (NMEs, or products with ingredients never before marketed in the United States) within their PDUFA goal dates. SGP and SEPR would be interested to learn this. <g> Unless they are not treating Claritin II as a NME? I would have thought it was - it's a metabolite of Claritin, and so has never been marketed before. Maybe some brave soul would like to navigate the bureaucracy and ask them? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next